Target intelligence / Profile preview

Glutamate dehydrogenase (GDH (also GLDH))

Target
GDH (also GLDH)
Molecular classification
Enzyme, Oxidoreductase
01

Overview

Glutamate dehydrogenase is a mitochondrial enzyme that catalyzes the reversible oxidative deamination of L-glutamate to α-ketoglutarate and ammonia, using NAD^+^ or NADP^+^ as cofactors. This reaction connects amino acid catabolism with the tricarboxylic acid cycle, making glutamate dehydrogenase a central player in both carbon and nitrogen metabolism across prokaryotes, plants, and animals[4][6][8]. In humans, it is encoded primarily by two genes—*GLUD1* and *GLUD2*. The enzyme typically forms a homohexameric structure composed of six identical subunits[9]. Glutamate dehydrogenase activity is tightly regulated allosterically. It can be inhibited by GTP, ATP, palmitoyl-CoA, Zn^2+^ ions, and EGCG; it is activated by ADP and certain amino acids such as leucine. Mutations affecting its regulatory regions can lead to diseases such as hyperinsulinism/hyperammonemia syndrome due to loss of sensitivity to inhibition by GTP[7]. In mammals—including humans—the equilibrium strongly favors glutamate oxidation rather than synthesis under physiological conditions because of low affinity for ammonia. The enzyme’s function varies among organisms. In bacteria it assimilates ammonia into amino acids; in plants it can operate bidirectionally depending on environmental conditions; in animals it mainly supports energy production from amino acids. Structural studies reveal significant conformational changes during catalysis that are essential for substrate binding and enzymatic activity[5][6]. No specific therapeutic drugs targeting glutamate dehydrogenase are currently listed in major databases based on these search results. However, its central metabolic role makes it an important target for research into metabolic disorders involving nitrogen balance or mitochondrial dysfunction. Notable safety concerns include potential toxicity from dysregulated ammonia production if GDH function becomes abnormal—a risk factor particularly relevant to inherited mutations causing hyperactivity of this enzyme[4][7].

Other names
GDHGLDHGlutamate dehydrogenase 1 (GLUD1)Glutamate dehydrogenase 2 (GLUD2)
02

Biological functions

Amino acid metabolismNitrogen metabolismEnergy metabolism (linking carbon and nitrogen cycles)
03

Disease associations

Hyperinsulinism/hyperammonemia syndromeNeurodegenerative disease
04

Safety considerations

Risk of hyperammonemia if enzyme activity is dysregulated

Beyond the preview

Go deeper on Glutamate dehydrogenase (GDH (also GLDH)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate dehydrogenase (GDH (also GLDH)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call